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INTRODUCTION
Breast cancer, the most common malignancy in 
women, is a heterogeneous disease with substantial 
diversity in histological and molecular characteristics that 
require specialized therapeutic interventions [1]. Most 
cases are classified as ‘sporadic’ breast carcinoma caused 
by genetic changes that occur over time [2], and only a 
small percentage (5-10%) of cases are of hereditary origin. 
The estrogen receptor (ER), the progesterone receptor (PR) 
and human epidermal growth factor receptor 2 (HER2) are 
the molecular biomarkers currently used in routine clinical 
practice to help make treatment decisions for breast cancer 
[3]. Triple-negative breast cancer (TNBC), which was 
named for the absence of ER, PR, and HER2 expression, 
is the most aggressive breast cancer subtype. TNBC has 
a high propensity for metastasis and a poor prognosis 
[4]. Current treatment modalities for TNBC are limited 
to surgery, radiation, and systemic chemotherapy due to 
the lack of more specific therapeutic targets. However, 
patients often experience early relapse from distant 
tumor metastasis even if they initially respond well to the 
treatments. Over the past few decades, tremendous effort 
has been expended in the search for a molecular targeted 
therapy for TNBC with limited success [5].
MicroRNAs (miRNAs) are small, non-coding, 
endogenous RNA molecules involved in gene regulation 
that are located in introns of protein-coding genes, 
introns of non-coding genes, or exons of non-coding 
genes. These small (18–25 nucleotides long) non-coding 
RNAs function as post-transcriptional regulators of gene 
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ABSTRACT
Triple-negative breast cancer is the most aggressive breast cancer subtype. 
The aim of our study was to investigate the functional role of both miR-101 and 
MCL-1 in the sensitivity of human triple-negative breast cancer (TNBC) to paclitaxel. 
We found that the expression of miR-101 was strongly decreased in triple-negative 
breast cancer tissues and cell lines. The expression of miR-101 was not associated 
with clinical stage or lymph node infiltration in TNBC. Ectopic overexpression of miR-
101 inhibit growth and induced apoptosis in vitro and suppressed tumorigenicity 
in vivo. MCL-1 was significantly overexpressed in most of the TNBC tissues and cell 
lines. Luciferase assay results confirmed MCL-1 as a direct target gene of miR-101. 
MiR-101 inhibited MCL-1 expression in TNBC cells and transplanted tumors. There 
was a negative correlation between the level of expression of miR-101 and MCL-1 in 
TNBC tissues. Suppression of MCL-1 enhanced the sensitivity of MDA-MB-435 cells to 
paclitaxel. Furthermore, miR-101 increased paclitaxel sensitivity by inhibiting MCL-1 
expression. Our findings provide significant insight into the molecular mechanisms of 
TNBC carcinogenesis and may have clinical relevance for the development of novel, 
targeted therapies for TNBC.
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expression by binding to the 3’ untranslated region (UTR) 
of target mRNAs and promoting mRNA degradation or 
translational repression[6]. Several studies demonstrated 
that miRNAs can inhibit the expression of oncogenes and 
tumor suppressors [7]. 
Furthermore, several miRNAs that play a crucial 
role in TNBC biology have been identified, and these 
miRNAs may have therapeutic implications. The causal 
involvement of microRNAs in breast cancer and the 
possible use of these small non-coding RNA molecules 
as biomarkers have been extensively studied, and those 
studies have generated promising results. Utilizing 
miRNAs as a therapeutic tool might be an innovative 
treatment approach, especially for tumor subgroups, such 
as TNBC, which cannot be treated with efficient and 
specific therapies [8]. In breast cancer, miRNA expression 
profiling using microarray technology, combined with 
some histopathological features, such as ER, PR and HER2 
status, has been established as a useful tool for classifying 
tumors [9]. MicroRNA-101 (miR-101) expression is 
negatively associated with tumor growth and blood vessel 
formation in several solid epithelial cancers, including 
breast cancer. Researchers have confirmed that miR-101 
acts as a tumor suppressor in gliomas [10]. The expression 
of miR-101 was decreased in human breast cancer tissues 
and inhibited cellular proliferation as well as invasiveness 
by targeting Stmn1 [11]. MAGI-2 suppression by miR-101 
reduces PTEN activity, leading to Akt activation in MCF-7 
breast cancer cells [12]. However, the role of miR-101 in 
TNBC remains elusive.
Myeloid cell leukemia 1 (MCL-1), a pro-survival 
member of the Bcl-2 (B-cell CLL/lymphoma 2) family, 
has been associated with the aberrant expression of pro-
survival Bcl-2 family proteins and tumorigenesis as well 
as resistance to chemotherapies [13]. Previous studies 
have demonstrated that several miRNAs induce apoptosis 
by targeting MCL-1 in nasopharyngeal carcinoma [14], 
acute myeloid leukemia [15] and ovarian cancer [16]. 
Our previous study showed that MCL-1 could be targeted 
with miR-26a in breast cancer [17]. Although studies have 
shown that MCL-1 is a target of miR-101 in lung cancer 
[18] and endometrial cancer cells [19], the roles of MCL-1 
and miR-101 in drug sensitivity have not been identified.
The goal of the present study was to identify 
“druggable” targets for TNBC to develop new treatment 
options. In this study, we analyzed the expression of 
miR-101 by using a triple-negative breast cancer tissue 
microarray. Previous investigations led us to study MCL-
1, a putative target of miR-101. After demonstrating the 
mechanism of miR-101 in in vitro and in vivo models, 
we hypothesized that miR-101 could be involved in the 
pathogenesis of breast cancer. In this study, miR-101 was 
considered a potential therapeutic target for TNBC.
RESULTS
Expression of miR-101 is decreased in TNBC cell 
lines and tissues
The miR-101 expression was decreased in seven of 
the eight breast cancer cell lines (BT-483, T47D, MCF-
7, SKBR3, BT-474, MDA-MB-435, MDA-MB-231, and 
MDA-MB-468) compared to the normal human mammary 
epithelial cell line MCF-10A (Figure 1A). These results 
indicated that miR-101 had lower expression in basal-
like cell lines compared to luminal cell lines. qRT-PCR 
revealed a decrease in miR-101 expression in 16 of 22 
TNBC samples (72.7%) (Figure 1B). Then, using ISH, we 
found that miR-101 expression was decreased in 56 of 86 
samples (65.1%) (Figure 1C). No significant correlations 
between miR-101 expression and age or tumor size were 
found (Table 2).
MiR-101 suppresses the proliferation, apoptosis 
and tumorigenic capacity of TNBC cells
To explore the functional effects of miR-101 in 
TNBC cells, we performed an MTT assay, flow cytometry 
analysis and JC-1 staining in MDA-MB-435 and MDA-
MB-468 cells. As shown in Figure 2A, the rate of cell 
survival was considerably lower for cells transfected with 
miR-101 mimics compared to the respective controls. 
By contrast, the inhibition of miR-101 by miR-101-
LNA significantly increased cell survival compared to 
the control (Figure 2A). To assess whether this effect is 
mediated through the induction of cell apoptosis, flow 
cytometry analysis and JC-1 staining were performed. 
The rate of apoptosis in MDA-MB-435 cells was 
increased following transfection with miR-101 mimics. 
Meanwhile, the inhibition of miR-101 suppressed cell 
apoptosis in MDA-MB-435 cells (Figure 2C). We found 
that the overexpression of miR-101 resulted in reduced 
MMP and increased green fluorescence in MDA-MB-435 
cells (Figure 2D). Consistent with the in vitro results, the 
in vivo growth rate of MDA-MB-435 cells transfected 
with miR-101 mimics was significantly slower than the 
growth rate of the controls, while the miR-101-LNA 
group demonstrated a faster growth rate (Figure 2E). 
These observations provide strong evidence that the 
overexpression of miR-101 significantly suppresses the 
growth of TNBC cells in vitro and in vivo.
Transfection of miR-101 sensitizes TNBC cells to 
paclitaxel by inducing apoptosis
In this study, ectopic overexpression of miR-101 
increased paclitaxel sensitivity, whereas the inhibition 
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of miR-101 decreased paclitaxel sensitivity in MDA-
MB-435 cells (Figure 3A). Our results showed that 
enhanced expression of miR-101 caused a significant 
reduction in MMP, an increase in green fluorescence and 
an increase in the rate of apoptosis in MDA-MB-435 cells 
after paclitaxel treatment (Figure 3B and 3C). To further 
confirm these results, the levels of apoptotic markers were 
detected in transfected MDA-MB-435 cells by Western 
blot analysis after treatment with paclitaxel. First, we 
detected the effect of paclitaxel on apoptosis in MDA-
MB-435 cells. Increasing doses of paclitaxel enhanced the 
expression of cleaved caspase-3 and PARP (Figure 3D). 
Western blot analysis showed that the overexpression of 
miR-101 significantly increased the expression of cleaved 
caspase-3 and PARP (Figure 3E).
MCL-1 is a target of miR-101 in breast cancer 
cells
TargetScan was used to help identify miR-101 
targets in human TNBC. Among the candidate target 
genes, the algorithm predicted MCL-1 as a target (Figure 
4A). The miR-101 mimics, but not miR-ctr, specifically 
Table 1: Clinicopathologic characteristics of patients
Characteristics Cohort 1 Cohort 2TNBC (n = 22) TNBC (n = 86)
Age (mean ± standard deviation) 47.8 ± 14.5 48.5 ± 11.2
Tumor size (cm) 6.8 ± 1.4 6.3 ± 1.1
Stage
I-II 15 61
III- IV 7 25
Lymph node
Not infiltrated 10 41
Infiltrated 12 45
Figure 1: Expression of miR-101 is decreased in TNBC. A. miR-101 expression was determined by quantitative RT-PCR in 
one normal mammary cell line, five tumor cell lines with a luminal transcriptional profile and three tumor cell lines with a basal-like 
transcriptional profile. miR-101 expression was normalized using U6 RNA expression. Error bars represent standard deviations (SD) for 
three replicates in one experiment. B. miR-101 expression in 22 paired TNBC specimens and the corresponding paired normal adjacent 
tissues are shown in a column analysis. C. Representative images of miR-101 expression as determined by ISH.
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Figure 2: MiR-101 suppresses proliferation and induces apoptosis of TNBC. A. MDA-MB-435 and MDA-MB-468 cell lines 
were transfected with miR-101 mimics, miR-101 inhibitors or their controls. Cell viability was determined using the MTT assay at 48 h 
post-transfection. *p < 0.05, **p < 0.01. The data represent the mean ± SD of three independent experiments. B. MDA-MB-435 and MDA-
MB-468 cells were transfected with miR-101 mimics or scramble mimics (upper panel). The effect of transfection on the levels of miR-101 
expression was determined by qRT-PCR. **p < 0.01 vs. control. C. Apoptosis was evaluated by analyzing Annexin V-FITC and propidium 
iodine staining by FACS. D. MDA-MB-435 cell lines were transfected with miR-101 mimics, miR-101 inhibitors, or control sequences. 
Mitochondrial membrane potential (MMP, Δψm) was determined at 48 h post-transfection. Green indicates apoptosis. E. MDA-MB-435 
cells were subcutaneously injected into nude mice. Then, the effects of intratumoral injection of 40 μL of scramble, miR-101 mimic or 
control, or miR-101 inhibitors in PBS on tumor volume was examined. The average tumor volumes are shown (n = 5 for both experimental 
groups) starting from the first injection and continuing until after the mice were killed at day 32. After 32 days, the mice were euthanized, 
necropsies were performed, and the tumors were weighed. All data are shown as the mean ± SD, **p < 0.01.
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Figure 3: Transfection of miR-101 sensitizes breast cancer cells to paclitaxel-induced apoptosis. A. The kinetics of the 
effect of miR-101 on breast cancer cell viability. MDA-MB-435 cells were transiently transfected with the indicated liposomal complexes, 
and the control group was measured for cell viability at 48 h post-transfection. Then, the cells were treated with different doses of paclitaxel. 
Data represent the mean ± SD of three independent experiments. *p < 0.05. B. MDA-MB-435 cells were transfected with paclitaxel, 
miR-101 mimics, miR-101 inhibitors or a combination. Mitochondrial membrane potential (MMP, Δψm) was determined at 48 h post-
transfection. Green indicates apoptosis. C. MDA-MB-435 cells were transfected with paclitaxel, miR-101 mimics, miR-101 inhibitors or 
a combination. The apoptotic cells were evaluated with Annexin V-FITC and propidium iodine staining and then analyzed by FACS. D. 
MDA-MB-435 cells were transfected with different doses of paclitaxel. Cleaved caspase-3 and cleaved PRAP protein levels were evaluated 
by Western blot. E. MDA-MB-435 cell lines were treated with paclitaxel and transfected with miR-101 mimics, miR-101 inhibitors or a 
combination. Cleaved caspase-3 and cleaved PRAP protein levels were evaluated by Western blot.
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decreased luciferase expression of the MCL1-3’-UTR-
wt reporter. By contrast, no change in relative luciferase 
expression was observed in cells transfected with the 
MCL1-3’-UTR-mut reporter (Figure 4B). These results 
suggest that MCL-1 is a direct target of miR-101. The 
results of qRT-PCR and Western blot analyses showed 
that enhanced expression of miR-101 by miR-101 
mimics in MDA-MB-435 and MDA-MB-468 cells led 
to the downregulation of endogenous MCL-1 mRNA and 
decreased protein levels. Accordingly, the inhibition of 
endogenous miR-101 by a miR-101 inhibitor (miR-101-
LNA) resulted in the upregulation of endogenous MCL-1 
mRNA and protein levels compared to the negative control 
(Figure 4C and 4D). In transplanted tumors, the expression 
of MCL-1 was decreased in the miR-101-treated group 
(Figure 4E). The expression of MCL-1 mRNA was 
significantly increased in 77.2% (17/22) of tumor tissues 
(Figure 4F), and the protein level was overexpressed in 
all three TNBC cell lines (Figure 4H). Furthermore, miR-
101 expression was negatively correlated with MCL-1 
expression in TNBC tissues (R = 0.555, P < 0.001; Figure 
4G).
MCL-1 mediates the suppressive functions of 
miR-101 in TNBC cells
The rate of cell survival was considerably lower after 
transfection with MCL-1 siRNA compared to respective 
controls in MDA-MB-468 and MDA-MB-435 cells. 
By contrast, the upregulation of MCL-1 by an MCL-1 
overexpression vector significantly increased cell survival 
compared to the control (Figure 5A). In MDA-MB-468 
and MDA-MB-435 cells, MCL-1 overexpression could 
reverse the inhibition induced by miR-101. However, 
MCL-1 knockdown could erase the effect of the miR-101 
inhibitor (Figure 5B). MCL-1 overexpression decreased 
the rate of apoptosis in MDA-MB-435 cells. miR-101 
recovered the effect of MCL-1 suppression on apoptosis 
in MDA-MB-435 cells. MCL-1 knockdown increased 
the rate of apoptosis in MDA-MB-435 cells. miR-101 
inhibition interrupted the induction of apoptosis in MDA-
MB-435 cells by MCL-1 siRNA (Figure 5C). MCL-1 
knockdown resulted in reduced MMP and increased green 
fluorescence. Additionally, the overexpression of MCL-1 
could attenuate the effect of miR-101 on MMP in MDA-
MB-435 cells (Figure 5D). The upregulation of MCL-
1 suppressed the expression of cleaved caspase-3 and 
cleaved PARP, and this effect on MCL-1 was weakened 
by miR-101. Conversely, inhibition of MCL-1 enhanced 
the levels of cleaved caspase-3 and cleaved PARP, and this 
effect on MCL-1 was abated by miR-101 (Figure 5E).
MCL-1 mediates miR-101-induced paclitaxel 
sensitivity in TNBC cells
MCL-1 overexpression promotes the proliferation 
of MDA-MB-435 cells incubated with different doses of 
paclitaxel. By contrast, MCL-1 knockdown suppressed 
cell proliferation (Figure 6A). In paclitaxel-treated MDA-
MB-435 cells, miR-101 induced green fluorescence. 
There was still orange fluorescence after co-transfection 
with a MCL-1-overexpressing vector and miR-101 in 
MDA-MB-435 cells (Figure 6B). These results indicated 
that MCL-1 overexpression could attenuate the effect of 
miR-101 on MMP in MDA-MB-435 cells. Additionally, 
MCL-1 overexpression could attenuate paclitaxel or 
paclitaxel combined with miR-101-induced apoptosis 
in MDA-MB-435 cells (Figure 6C). In addition, MCL-1 
Table 2: Analysis of the correlation between miR-101 expression and 
clinicopathological parameters in breast cancer
Viable Cases miR-101
low high p value
Age (years)
< 50
≥ 50
43
43
28
28
15
15 0.589
Tumor size (cm)
≤ 2
> 2
23
63
14
42
9
21 0.400
Stage
I-II
III- IV
61
25
34
22
27
3 0.003
Lymph node
Not infiltrated
Infiltrated
41
45
19
37
22
18 0.032
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overexpression also partly suppressed apoptosis-associated 
cleaved caspase-3 and PARP protein levels, which were 
increased by paclitaxel and/or miR-101 (Figure 6D).
DISCUSSION
Emerging research has demonstrated that 
miRNAs play important roles in tumor development 
and progression, including breast cancer [7, 10, 20, 21]. 
While it has been reported previously that suppression 
of miR-101 leads to the overexpression of MCL-1 in 
hepatocellular carcinoma and non-small-cell lung cancer 
[18, 22], the relationship between MCL-1 and miR-101 
and their biological relevance in breast cancer have not yet 
been fully determined, especially in TNBC. In this study, 
the expression of miR-101 was decreased and inversely 
correlated with MCL-1 expression in all basal-like cell 
Figure 4: MiR-101 directly targets MCL-1. A. MiR-101 was predicted to bind to the MCL-1 3’-UTR using TargetScan and 
microRNA online software. B. A luciferase assay was performed on MDA-MB-435 cells co-transfected with miR-101 mimics, a scrambled 
control, miR-101 inhibitors, a control and a luciferase reporter containing MCL-1 3’-UTR (MCL-1-wt) or mutant constructs in which the 
five nucleotides of the miR-101 binding site were mutated (MCL-1-mut). An empty luciferase reporter construct was used as a negative 
control. *p < 0.05 vs. scramble. C. MDA-MB-435 and MDA-MB-468 cell lines were transfected with miR-101 mimics, miR-101 inhibitors 
or their controls. The mRNA expression of MCL-1 was detected by qRT-PCR. D. The effect of miR-101 mimics or miR-101 inhibitors on 
the protein expression of MCL-1 was determined by Western blot in both the MDA-MB-435 and MDA-MB-468 cell lines. β-actin was 
used as a loading control. E. In situ hybridization was used to detect the expression of miR-101, and immunohistochemistry was used to 
detect the expression of MCL-1 in transplanted tumor tissues in the scramble, miR-101 mimics, control and miR-101 inhibitor groups. 
F. The expression of MCL-1 in 22 paired TNBC specimens and the corresponding paired normal, adjacent tissues are shown in a column 
analysis. G. The correlation between miR-101 and MCL-1 expression in breast cancer tissues was analyzed by comparing miRNA and 
mRNA expression. H. The expression of MCL-1 was determined by qRT-PCR in one normal mammary cell line, five tumor cell lines with a 
luminal transcriptional profile and three tumor cell lines with a basal-like transcriptional profile. miR-101 expression was normalized using 
U6 RNA expression. Error bars represent standard deviations (SD) for three replicates in one experiment.
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Figure 5: MiR-101 suppresses proliferation and induces apoptosis of TNBC by targeting MCL-1. A. MDA-MB-435 and 
MDA-MB-468 cells were transfected with an MCL-1 overexpression vector or mock vector. The effect of transfection on the levels of 
miR-101 expression was determined by qRT-PCR. **p < 0.01 vs. control. B. MDA-MB-435 cells were transfected with miR-101 mimics, 
miR-101 inhibitors, a MCL-1 overexpression vector, MCL-1 siRNA or a combination. The expression of MCL-1 mRNA was detected by 
qRT-PCR. C. MDA-MB-435 cells were transfected with miR-101 mimics, miR-101 inhibitors, an MCL-1 overexpression vector, MCL-
1 siRNA or a combination. The apoptotic cells were evaluated by Annexin V-FITC and propidium iodine staining and then analyzed by 
FACS. D. MDA-MB-435 cells were transfected with miR-101 mimics, miR-101 inhibitors, an MCL-1 overexpression vector, MCL-1 
siRNA or a combination. Mitochondrial membrane potential (MMP, Δψm) was determined at 48 h post-transfection. Green indicates 
apoptosis. E. MDA-MB-435 cells were transfected with miR-101 mimics, miR-101 inhibitors, a MCL-1 overexpression vector, MCL-1 
siRNA or a combination. Cleaved caspase-3 and cleaved PRAP protein expression was evaluated by Western blot.
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lines and in the majority of TNBC tissues. The results 
from the luciferase reporter assays confirmed that MCL-1 
represents a direct target gene of miR-101 in TNBC cells. 
We assessed the effect of miR-101 and MCL-1 on breast 
cancer growth both in vitro and in vivo. Using two TNBC 
cell lines, we were able to show that miR-101 suppress 
Figure 6: MiR-101 sensitizes TNBC cells to paclitaxel-induced apoptosis by targeting MCL-1. A. The kinetics of the effect 
of MCL-1 on breast cancer cell viability. MDA-MB-435 cells were transiently transfected with the indicated liposomal complexes, and the 
control group was measured for cell viability at 48 h post-transfection. Then, the cells were treated with different doses of paclitaxel. The 
data represent the mean ± SD of three independent experiments. *p < 0.05. B. MDA-MB-435 cells were transfected with miR-101 mimics, 
an MCL-1 overexpression vector or a combination. All the cells were treated with paclitaxel. Mitochondrial membrane potential (MMP, 
Δψm) was determined at 48 h post-transfection. Green indicates apoptosis. C. MDA-MB-435 cells were transfected with miR-101 mimics, 
an MCL-1 overexpression vector or a combination. All the cells were treated with paclitaxel. The apoptotic cells were evaluated by Annexin 
V-FITC and propidium iodine staining and then analyzed by FACS. D. MDA-MB-435 cells were transfected with miR-101 mimics, an 
MCL-1 overexpression vector or their combined groups. All the cells were treated with paclitaxel. Cleaved caspase-3 and cleaved PRAP 
protein levels were evaluated by Western blot.
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the expression of MCL-1, both at the transcriptional and 
the post-transcriptional level. miR-101 overexpression 
significantly suppressed proliferation in vitro. These 
effects appeared to be mediated by inhibition of the MCL-
1 oncogene, which led to cell apoptosis. Furthermore, 
transfection of miR-101 mimics effectively suppressed 
the tumorigenicity of TNBC cells in a nude mouse model. 
Other studies have obtained similar results. Specifically, 
miR-101 suppressed tumor progression by targeting MCL-
1 in hepatocellular carcinoma [23] and lung cancer [24].
Studies performed by Koss B [25] indicate that 
endogenous MCL-1 has anti-apoptotic activity that 
promotes survival during BCR-ABL transformation in 
established BCR-ABL(+) leukemia. MCL-1 mediates the 
inhibition of osteosarcoma pathogenesis by miR-133a 
[26]. MCL-1 is overexpressed in human glioblastoma, 
which confers a survival advantage to tumor cells. 
Inhibition of MCL-1 potentiates temozolomide-induced 
apoptosis in gliomas [27]. In our study, we were able to 
show that the suppression of MCL-1 significantly inhibits 
proliferation and induces apoptosis in vitro. 
Apoptosis is a critical part of various biological 
processes, and it represents a regulated cellular 
suicide mechanism that is characterized by nuclear 
condensation, cell shrinkage, membrane blebbing and 
DNA fragmentation. Apoptosis is also involved in 
carcinogenesis. It has been reported that miRNAs play 
important roles in inducing apoptosis [28] and sensitizing 
tumor cells to chemotherapeutic agents [29]. For example, 
Wang and colleagues have demonstrated that miR-101 
sensitizes human bladder cancer cells to gambogic acid-
induced apoptosis by inhibiting EZH2 expression [30]. 
Although a number of effective options have been 
developed for the treatment of HER2-overexpressing 
diseases, TNBC remains a subtype that is difficult to treat. 
Taxanes are considered to be some of the most active 
classes of compounds that work against breast cancer 
[31], but a major obstacle remains for successful cancer 
treatment. Paclitaxel inhibits proliferation and induces 
apoptosis in a variety of cancers. Shi et al. demonstrated 
that a PARP inhibitor reduces proliferation and increases 
apoptosis in breast cancer cells[32]. Additional data 
has shown that paclitaxel can induce apoptosis in 
human MDA-MB-231 breast cancer cells in a caspase-
dependent manner. In our study, we were able to show 
that miR-101-mediated MCL-1 silencing sensitized 
TNBC cells to paclitaxel-induced apoptosis, whereas 
antagomir-mediated downregulation of endogenous 
miR-101 reversed the apoptotic effect. Future studies 
are needed to further elucidate the signaling pathways 
that control miR-101-mediated apoptosis in TNBC. In 
this study, we demonstrated that the overexpression of 
miR-101 enhanced the expression of apoptosis-related 
cleaved caspase 3 and PARP by targeting MCL-1 and 
that miR-101 could enhance the expression of paclitaxel-
induced cleaved caspase 3 and PARP in TNBC cells. 
These results show that miR-101 transfection increases 
chemotherapeutic drug-induced apoptosis in TNBC.
Our data suggest that the tumor suppressor miR-101 
represses TNBC progression and sensitizes TNBC cells 
to paclitaxel treatment by directly targeting MCL-1. Our 
findings provide significant insights into the molecular 
mechanisms underlying breast carcinogenesis and may 
have relevance for the development of novel, targeted 
therapies for TNBC.
MATERIALS AND METHODS
Cell lines and transfection
The following cell lines were obtained from the 
American Type Culture Collection (Manassas, VA, USA) 
and were passaged in our laboratory for less than six 
months after the frozen aliquots were thawed: five breast 
cancer cell lines with a luminal transcriptional profile (BT-
483, T47D, MCF-7, SKBR3 and BT-474), three breast 
cancer cell lines with a basal-like transcriptional profile 
(MDA-MB-435, MDA-MB-231, and MDA-MB-468) and 
a normal mammary epithelial cell line (MCF-10A). Basal-
like breast cancer is also known as triple-negative breast 
cancer (TNBC) [33]. All cells were maintained according 
to the supplier’s instructions. Before use, all cell lines were 
authenticated with short tandem repeat DNA profiling and 
were found to be free of mycoplasma infection. Plasmids, 
miRNAs, and small interfering RNAs (siRNAs) were 
transfected into the cells at the indicated concentrations 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instructions.
Clinical samples
Tissue samples from 22 cases of TNBC and the 
corresponding paired normal adjacent tissues, collected 
from September 2010 to May 2011 (Table 1), were 
analyzed using quantitative real-time PCR (qRT-PCR). 
Resected cancerous tissues and paired normal mammary 
tissues were immediately cut into pieces and stored in 
RNAlater (Ambion). The tissue microarrays consisted of 
86 TNBC tissues (including the 22 collected samples). 
Histopathology was used to confirm TNBC in the samples 
collected from September 2010 to September 2012. The 
matched paracarcinoma tissues were used as the control 
samples. The specimens were stored in the Department 
of Specimens and Resources at Sun Yat-Sen University 
Cancer Center. The specimens were obtained during 
surgery and were formalin fixed and embedded in paraffin 
using standard methods. Immunohistochemistry of ER, 
PR and HER2 expression was performed in the Pathology 
Department of Sun Yat-Sen University Cancer Center. 
None of the patients included in the present study had 
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received any chemotherapy or radiation therapy prior to 
the study, and their complete clinical data were available 
and reviewed, including age, histologic type, lymph node 
status, tumor size, stage, local relapse, distant metastatic 
relapse, ER status, PR status, and HER2 status. Histologic 
type was based on the TNM staging system, and the 
types were reclassified according to WHO classification 
and tumor stage (American Joint Committee on Cancer 
classification). Patient follow-up included a review of their 
records and telephone calls. The patients were grouped 
according to age, lymph node status, tumor size and stage. 
This study was approved by the Ethics Committee of 
Sun Yat-Sen University Cancer Center Health Authority. 
Written informed consent for participation in the study 
was obtained from all participants. The procedures for 
collecting and using tissues from the patients were in 
accordance with the ethical standards established in the 
Declaration of Helsinki.
qRT-PCR
Total RNA was extracted from cells with TRIzol 
reagent (Invitrogen, Carlsbad, USA). Reverse transcription 
and qRT-PCR reactions were performed with a SYBR-
green-containing PCR kit (Qiagen, Germantown, USA). 
The fold change was determined as 2-ΔΔCt. The Ct is the 
fractional cycle number at which the fluorescence of each 
sample passes the fixed threshold. ΔCt was calculated 
by subtracting the Ct of snRNA U6 from the Ct of the 
miRNA of interest. ΔΔCt was calculated by subtracting 
the ΔCt of the reference sample (paired non-tumorous 
tissue for the surgical samples) from the ΔCt of each 
sample. The primers for qRT-PCR detection of MCL-
1 mRNA (F: TAAGGACAAAACGGGACTGG; R: 
CCTCTTGCCACTTGCTTTTC) were synthesized by 
Invitrogen. All qRT-PCR was performed with a Bio-Rad 
C1000 Multicolor Real-Time PCR Detection System 
(USA).
In situ hybridization (ISH) analysis
In situ hybridization procedures were carried out 
as previously described. miR-101 miRCURYTM LNA 
custom detection probes (Exiqon, Vedbaek, Denmark) 
were used for ISH. The 5’-3’ sequence (enhanced with 
LNA) was UACAGUACUGUGAUAACUGAA with 
digoxigenin (DIG) at the 5’ and 3’ ends. Hybridization, 
washing, and scanning were performed according to the 
manufacturer’s instructions. Staining intensity was scored 
as 0 (negative), 1+ (weak), 2+ (medium) or 3+ (strong). 
Low expression was defined as a staining intensity of 0, 
1, 2 or 3 with < 10% of cells being stained or an intensity 
of 0 or 1 with < 50% of cells stained. High expression 
was defined as an intensity of 2 or 3 with < 10% of cells 
stained or an intensity of 1, 2 or 3 with < 50% of cells 
stained.
Vector construct
An MCL-1-expressing vector was constructed. Full-
length MCL-1 cDNA was purchased from GeneCopoeia 
TM (USA) and was subcloned into the pcDNA3.1(+) 
vector. The 3’UTR of MCL-1 (pMIR-MCL-1) or the 
3’UTR with mutated binding sites for miR-101 (pMIR-
MCL-1-mut) was synthesized by Invitrogen (China) and 
inserted into pMIR-REPORT, which expresses the firefly 
luciferase plasmid (Promega). 
Dual-Luciferase reporter assay and 3’UTR 
binding site mutagenesis
MDA-MB-435 cells (6×104) were seeded in 24-
well plates immediately prior to transfection. The pMIR-
Mcl1 and pMIR-Mcl1-mut constructs were transfected 
into MDA-MB-435 cells using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. 
The miR-101 mimic was co-transfected where indicated. 
Forty-eight hours post-transfection, the cells were 
assayed for both firefly and renilla luciferase with the 
dual luciferase glow assay (Promega). Transfection 
experiments were performed in duplicate, and each 
experiment was repeated at least three times.
Cell proliferation assay and cell apoptosis analysis
Cell proliferation at 48 h was determined using the 
cell proliferation reagent MTT (Roche Applied Science, 
Mannheim, Germany) according to the manufacturer’s 
protocol. For cell apoptosis analysis, the cells were 
transfected as described in the previous section, and the 
apoptotic rate was detected with Annexin V/FITC staining 
and flow cytometry (FACSCalibur flow cytometer; BD 
Biosciences, Franklin Lakes, NJ, USA).
Detection of mitochondrial membrane potential 
(MMP, Δψm) using JC-1
To measure the mitochondrial membrane potential 
(Δψm), 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzim
idazolylcarbocyanine iodide (JC-1), which is a sensitive 
fluorescent probe kit for Δψm, was used on the cells 
(Biyuntian Biochemistry Limited Company, China). 
Treated or untreated cells were cultured in 24-well plates 
for 24 h, washed with PBS and incubated with a working 
solution of JC-1 for 20 min at 37°C. Then, the cells were 
rinsed twice with PBS, stained with 1 mL of 10% DMEM 
medium containing 5 μmol/L JC-1, resuspended in 1 mL 
of ice-cold PBS, washed with PBS and resuspended in 
500 μL of PBS. The stained cells were analyzed using a 
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fluorescence microscope to determine color changes in the 
florescence from red to green.
Immunohistochemical staining
Immunohistochemical staining was performed 
using an UltraSensitive S-P Kit (Maixin Biotechnology 
Company, Fuzhou, China). The color was developed 
using DAB as the chromogen. Then, the slides were 
counterstained with Mayer’s hematoxylin and mounted 
for evaluation under a microscope (OLYMPUS BX-51, 
Osaka, Japan). Two independent pathologists who were 
blinded to the clinicopathological information scored the 
samples. Staining was scored for intensity (1, 0+; 2, 1+; 
3, 2+; 4, 3+) as well as the percentage of membranous 
and cytoplasmic staining in malignant cells (1, 0-25%; 
2, 26-50%; 3, 51-75%; 4, 76-100%). The final score was 
obtained by multiplying the intensity score by the score 
for the percentage counts. A score of < 8 was considered 
to be low expression, and a score of > 8 was considered to 
be high expression.
Western blot
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed on protein 
lysates from the cells, and the target proteins were detected 
with primary antibodies recognizing MCL-1 (Santa 
Cruz, USA), Caspase-3, Cleaved PARP and GAPDH 
(Cell Signaling). After incubation with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Jackson ImmunoResearch), the protein bands 
were visualized using enhanced chemiluminescence 
(ECL) Western blot detection reagents and then analyzed 
with the Bio Image Intelligent Quantifier 1-D (Version 
2.2.1, Nicon-BioImage Ltd., Japan).
Human tumor xenograft model
To investigate the antitumor effects of miR-101 in 
vivo, female BALB/c-nude mice (4–6 weeks old; Vital 
River Laboratories Animal, Beijing, China) were injected 
subcutaneously in the right fourth mammary gland with 
5×106 MDA-MB-435-Luc cells in 100 μL of PBS with 
a 30-gauge needle. Tumor formation was monitored by 
palpation, and tumor size was measured twice per week 
using calipers. Tumor volume was calculated using the 
standard formula: tumor volume = (width2×length×π)/6. 
When the tumors reached ~50 mm3, the mice were 
noninvasively imaged using the IVIS In Vivo Imaging 
System (Xenogen, Alameda, CA) to confirm tumor 
growth. Then, the mice were randomly assigned to one 
of four groups (n = 10 mice per group): miR-LNA, miR-
101-LNA, miR-scramble or miR-101 mimics. All groups 
received intratumoral injections twice a week for three 
consecutive weeks. Mouse weight and tumor progression 
were monitored daily using the IVIS system with Living 
Imaging software (Xenogen). On day 32, the mice were 
euthanized by spinal dislocation, and the tumors and hearts 
were immediately harvested, weighed, and analyzed. 
All experiments were performed in accordance with 
institutional guidelines and were approved by the animal 
care and use committee at the University of Sun Yat-Sen 
University Cancer Center.
Statistical analysis
All values are expressed as the mean ± standard 
error of the mean. All experiments using cell lines were 
repeated a minimum of 3 times. Statistical significance 
was reported if the p-value was < 0.05 using an unpaired 
Student’s t-test.
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